Want to see TSE:BU full AI Analyst Report?
BU Stock Chart & Stats
C$1.73
C$0.00(0.00%)
At close: 4:00 PM EST
C$1.73
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$1.51 - C$3.24
Previous CloseN/A
Volume8.19K
Average Volume (3M)6.58K
Market Cap
C$24.43M
Enterprise ValueC$50.14M
Total Cash (Recent Filing)C$950.53K
Total Debt (Recent Filing)C$24.42M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Aug 17, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding12,692,942
10 Day Avg. Volume9,144
30 Day Avg. Volume6,578
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)-4.05
Price to Sales (P/S)10.37
P/FCF Ratio-2.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.16
Revenue Forecast (FY)C$14.00M
Bulls Say, Bears Say
Bulls Say
Proprietary IP & Licensing ModelBurcon’s asset-light, IP-centered business model monetizes patented extraction and purification methods via licensing, JV commercialization and tech services. That structure supports scalable, recurring revenue potential and limited incremental capex per license, durable if partners scale production.
Broad Commercial PipelineA 200+ project pipeline with 30+ active buyers signals validated demand and diversification across applications. This breadth reduces single-customer concentration risk, increases chances that scaling converts to sustained revenues, and supports durable commercial momentum over the coming months.
Production Scale & Quality CertificationsCommercial-scale production improvements plus BRC certification and allergen-free status materially lower customer onboarding friction and regulatory hurdles. These operational and quality credentials are durable advantages when competing for long-term supply agreements and repeat orders.
Bears Say
Deteriorating Balance SheetA sharp rise in leverage and a move to negative shareholders’ equity weaken financial flexibility and increase refinancing and covenant risks. This degraded capital structure makes executing growth plans more dependent on external, potentially dilutive or costly financing over the medium term.
Persistent Cash BurnConsistent and worsening negative operating and free cash flow indicate the business currently requires ongoing external funding to sustain operations and scale. That cash burn elevates liquidity risk, constrains reinvestment capacity, and makes timely execution on commercialization conditional on financing.
Small Revenue Base & Long Adoption CyclesDespite strong percentage growth, absolute revenue remains small and ingredient adoption typically takes 9–18 months. These structural timing lags slow conversion of pipeline into recurring sales, extend the path to profitability, and raise execution risk if partner demand or validation timelines slip.
Burcon Nutrascience News
BU FAQ
What was Burcon Nutrascience’s price range in the past 12 months?
Burcon Nutrascience lowest stock price was C$1.51 and its highest was C$3.24 in the past 12 months.
What is Burcon Nutrascience’s market cap?
Burcon Nutrascience’s market cap is C$24.43M.
When is Burcon Nutrascience’s upcoming earnings report date?
Burcon Nutrascience’s upcoming earnings report date is Aug 17, 2026 which is in 39 days.
How were Burcon Nutrascience’s earnings last quarter?
Burcon Nutrascience released its earnings results on Jun 24, 2026. The company reported -C$0.3 earnings per share for the quarter, missing the consensus estimate of -C$0.1 by -C$0.2.
Is Burcon Nutrascience overvalued?
According to Wall Street analysts Burcon Nutrascience’s price is currently Overvalued.
Does Burcon Nutrascience pay dividends?
Burcon Nutrascience does not currently pay dividends.
What is Burcon Nutrascience’s EPS estimate?
Burcon Nutrascience’s EPS estimate is -0.07.
How many shares outstanding does Burcon Nutrascience have?
Burcon Nutrascience has 12,692,942 shares outstanding.
What happened to Burcon Nutrascience’s price movement after its last earnings report?
Burcon Nutrascience reported an EPS of -C$0.3 in its last earnings report, missing expectations of -C$0.1. Following the earnings report the stock price went down -16.594%.
Which hedge fund is a major shareholder of Burcon Nutrascience?
Currently, no hedge funds are holding shares in TSE:BU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Burcon Nutrascience
Burcon NutraScience Corporation, along with its associated entities, is a Canadian enterprise specializing in the development and commercialization of plant-derived proteins and functional ingredients for the food and beverage sectors. Its extensive product line features Peazazz, a versatile pea protein suitable for a range of applications including dairy alternatives, ready-to-drink and dry-blended beverages, snack bars, baked goods, and meat substitutes. Also derived from peas, Peazac and Peazac 850 are tailored for plant-based meat alternatives, ready-to-mix powders and drinks, dairy-free options, and nutritional bars, particularly valued for their neutral taste profile and moderate textural properties. Among its canola-based proteins is Puratein, an isolate frequently utilized in meat alternatives such as burgers and sausages, as well as nutrition bars. Supertein, a pale-hued canola protein powder, is incorporated into non-dairy frozen desserts, egg replacers, plant-based marshmallows, ready-to-mix beverages, whipped toppings, and plant-based snack bars. Additionally, Nutratein, a canola protein composed of globulin and albumin, finds utility in meat and egg alternatives, alongside various other functional plant-based foods. Further expanding its offerings are Nutratein-PS and Nutratein-TZ, custom blends featuring its Peazac pea protein, alongside CLARISOY, a soy protein employed across sports nutrition beverages, citrus and fruit-flavored drinks, lemonades, powdered beverage mixes, and diverse other food and dietary items. Finally, MeritPro stands as a unique nutritional protein blend, distinguished by being allergen-free, gluten-free, dairy-free, non-GMO, and vegan-friendly. Originally incorporated in 1998 as Burcon Capital Corp., the firm rebranded to Burcon NutraScience Corporation in October 1999. Its corporate headquarters are situated in Vancouver, Canada.
BU Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong operational progress and accelerating commercial traction — material revenue growth (nearly sixfold YoY), expanding customer pipeline (200+ projects and 30+ active buyers), repeat orders, and significant production improvements (60% higher daily production). Management also demonstrated cost discipline (G&A -23%, R&D -65%) and secured partial financing with partner and insider support. Primary challenges are the small absolute revenue base ($2.3M), remaining facility capital work and capacity planning, lengthy customer adoption cycles (9–18 months), and ongoing liquidity/financing considerations. Overall, the positive operational momentum and validated customer demand outweigh the early-stage risks and financing needs, but execution against scaling and profitability targets remains critical.View all TSE:BU earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---





